Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea
article
OA: closed
CC0
⤵ 13 in-corpus citations
Abstract
OBJECTIVE: To compare the efficacy of the cyclooxygenase (COX)-2-specific inhibitor valdecoxib with naproxen sodium in treating menstrual pain associated with primary dysmenorrhea. METHOD: This single-center, double-blind, placebo-controlled, randomized, crossover study compared the efficacy and safety of single oral doses of valdecoxib 20 mg and 40 mg with naproxen sodium 550 mg, or placebo, with an option of treatment for up to 3 days, twice daily. Efficacy was assessed by time-weighted sum of total pain relief, sum of pain intensity difference, time-specific pain relief, and pain intensity difference over 12 hours, time to rescue medication or first re-medication, the percentage of patients taking rescue medication, and patient's global evaluation of study medication. RESULTS: Mean time-weighted sum of total pain relief and sum of pain intensity difference were significantly superior to placebo for the first 8 and 12 hours after the initial dose of valdecoxib 20 mg (P <.01) and 40 mg (P <.001). Valdecoxib 20 mg and 40 mg were comparable to naproxen sodium 550 mg for all efficacy measures. Other differences in efficacy measures favoring the higher dose of valdecoxib did not achieve statistical significance, with the exception of sum of pain intensity difference-12. Both doses of valdecoxib were well tolerated. CONCLUSIONS: Both valdecoxib 20- and 40-mg doses were effective and well tolerated for the treatment of primary dysmenorrhea. Valdecoxib 20 mg and 40 mg demonstrate analgesic efficacy, based on onset, magnitude, and duration of analgesia that is similar to naproxen sodium, making it a potential choice for treating women with primary dysmenorrhea.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (27)
- Dysmenorrhoea and Prostaglandins via openalex
- Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen: Effect on prostaglandin levels in menstrual fluid via openalex
- The Effect Of Flurbiprofen And Naproxen Sodium On Intra‐Uterine Pressure And Menstrual Pain In Patients With Primary Dysmenorrhea via openalex
- doi:10.1001/jama.282.20.1929 via openalex
- doi:10.1016/s0022-3565(25)23861-7 via openalex
- doi:10.1016/s0140-6736(94)91843-0 via openalex
- W38934519 via openalex
- doi:10.1073/pnas.91.8.3228 via openalex
- doi:10.1073/pnas.85.5.1412 via openalex
- doi:10.1073/pnas.91.25.12013 via openalex
- doi:10.1016/s0021-9258(18)68959-8 via openalex
- W2416971238 via openalex
- doi:10.1074/jbc.271.52.33157 via openalex
- doi:10.1089/jwh.1997.6.83 via openalex
- doi:10.1016/s0149-2918(00)80043-0 via openalex
- doi:10.1016/s0149-2918(99)80016-2 via openalex
- doi:10.1021/jm990577v via openalex
- doi:10.1016/s0149-2918(01)80088-6 via openalex
- doi:10.1097/00000539-200109000-00036 via openalex
- doi:10.1001/jama.275.5.376 via openalex
- doi:10.1016/0002-9343(88)90473-1 via openalex
- doi:10.1111/j.1471-0528.1984.tb15089.x via openalex
- doi:10.1016/s0149-2918(99)80045-9 via openalex
- doi:10.1016/s0029-7844(99)00360-9 via openalex
- doi:10.1016/s0021-9258(18)98774-0 via openalex
- doi:10.1074/jbc.271.26.15810 via openalex
- doi:10.1056/nejm199209103271101 via openalex
Cited by (13)
- Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials 2019
- Endometriosis 2013
- Optimal management of chronic cyclical pelvic pain: an evidence-based and pragmatic approach 2010
- Celecoxib in the treatment of primary dysmenorrhea: Results from two randomized, double-blind, active- and placebo-controlled, crossover studies 2009
- Endometriosis 2009
- Dismenorreas 2008
- Endocrine Regulation of Menstruation 2005
- Dysmenorrhoea 2005
- Valdecoxib for treatment of primary dysmenorrhea 2005
- Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data 2004
- Regression of endometrial explants in rats treated with the cyclooxygenase-2 inhibitor rofecoxib 2004
- Dysmenorrh� bei Jugendlichen 2004
- Cyclooxygenase-2 Inhibitors in Gynecologic Practice 2003
Source provenance
- openalex
- last seen: 2026-05-14T06:07:48.142452+00:00
License: CC0
· commercial use OK